← All Bioxytran, INC filings

Bioxytran, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

OQB
BIXT
Bioxytran, INC
10-K: Bioxytran Reports 2025 Financials, Advances Drug Development
Bioxytran, Inc. filed its annual report for the year ended December 31, 2025, detailing progress in its pharmaceutical development pipeline and financial status.
OQB
BIXT
Bioxytran, INC
10-K: Bioxytran Faces Going Concern Uncertainty Despite Efforts in Drug Development and Subsidiary Acquisition
Bioxytran's Form 10-K reveals ongoing losses and dependence on future financing for its drug development programs, including BXT-25 and ProLectin-Rx, despite recent subsidiary acquisition and IND approvals.
OQB
BIXT
Bioxytran, INC
10-K/A: Bioxytran Inc. Files Amended 10-K, Cites Material Weakness in Internal Controls
Bioxytran Inc. has filed an amended annual report on Form 10-K, restating its financials for 2023 and 2022 due to errors in share valuation and reporting, while also disclosing a material weakness in internal controls.
OQB
BIXT
Bioxytran, INC
10-K: Bioxytran Inc. Reports Full Year 2023 Results, Outlines Progress in Drug Development
Bioxytran, Inc. released its 2023 annual report, detailing financial results and advancements in its BXT-25 and ProLectin-Rx drug development programs.